Business
Conclusion of Hokkaido Evaluation Agreement
Conclusion of Hokkaido Evaluation Agreement.
About this update from Valirx Plc
[{"type":"text","content":"\n\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nConclusion of Hokkaido Evaluation Agreement\nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces the conclusion of the evaluation agreement with Hokkaido University, as announced on 16 December 2021 and extended on 6 December 2022.\nUnder this agreement, ValiRx committed to conducting a range of experiments following initial confirmation of the synthetic route and analysis. After overcoming initial challenges in synthesis and purification of the peptide, testing has been conducted on the product. However, the profile of the product has been found to be unsuitable for further development at this stage and the evaluation will now cease. As agreed, the data generated under the evaluation agreement will be provided to the originating academics at Hokkaido University to enable them to optimise the molecular profile. There is no further commitment to the project by ValiRx.\nDr Suzy Dilly, CEO of ValiRx commented: \"Although it's disappointing not to be able to progress this project further, this highlights the importance of our process of evaluating academic projects prior to full in-licensing. In addition to returning the data to Hokkaido, we have made recommendations for further work, and we will be following the scientific progress of project with interest.\"\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). The Directors of the Company take responsibility for this announcement.\n \nFor more information, please contact:\n \n\n\n\nValiRx plc\n \nDr Suzanne Dilly, CEO\n \n \n\n\nTel: +44 (0) 2476 796496\nwww.valirx.com\[email protected]\n \n \n\n\n\n\nV Formation (Public Relations)\n \nLucy Wharton - Senior PR Executive\nSue Carr - Director\n \n\n\n+44 (0) 115 787 0206\nwww.vformation.biz\n \[email protected]\[email protected]\n\n\n\n\nCairn Financial Advisers LLP (Nominated Adviser)\n \nLiam Murray/Jo Turner/Ludovico Lazzaretti\n \n\n\nTel: +44 (0) 20 7213 0880\n\n\n\n\nCenkos Securities p...